Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.16
JAZZ's Cash to Debt is ranked higher than
57% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. JAZZ: 1.16 )
JAZZ' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 1.16

Equity to Asset 0.58
JAZZ's Equity to Asset is ranked higher than
65% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. JAZZ: 0.58 )
JAZZ' s 10-Year Equity to Asset Range
Min: -0.82   Max: 0.76
Current: 0.58

-0.82
0.76
F-Score: 5
Z-Score: 6.23
M-Score: -2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 39.01
JAZZ's Operating margin (%) is ranked higher than
97% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. JAZZ: 39.01 )
JAZZ' s 10-Year Operating margin (%) Range
Min: -365.84   Max: 46.95
Current: 39.01

-365.84
46.95
Net-margin (%) 24.79
JAZZ's Net-margin (%) is ranked higher than
94% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. JAZZ: 24.79 )
JAZZ' s 10-Year Net-margin (%) Range
Min: -397.15   Max: 49.25
Current: 24.79

-397.15
49.25
ROE (%) 16.70
JAZZ's ROE (%) is ranked higher than
93% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. JAZZ: 16.70 )
JAZZ' s 10-Year ROE (%) Range
Min: -252.45   Max: 107.29
Current: 16.7

-252.45
107.29
ROA (%) 9.66
JAZZ's ROA (%) is ranked higher than
92% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. JAZZ: 9.66 )
JAZZ' s 10-Year ROA (%) Range
Min: -156.89   Max: 49.29
Current: 9.66

-156.89
49.29
ROC (Joel Greenblatt) (%) 775.15
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. JAZZ: 775.15 )
JAZZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6776.65   Max: 8375.22
Current: 775.15

-6776.65
8375.22
Revenue Growth (%) 47.60
JAZZ's Revenue Growth (%) is ranked higher than
96% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. JAZZ: 47.60 )
JAZZ' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 47.6
Current: 47.6

0
47.6
EBITDA Growth (%) 59.50
JAZZ's EBITDA Growth (%) is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. JAZZ: 59.50 )
JAZZ' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 75.9
Current: 59.5

0
75.9
EPS Growth (%) 61.70
JAZZ's EPS Growth (%) is ranked higher than
98% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. JAZZ: 61.70 )
JAZZ' s 10-Year EPS Growth (%) Range
Min: -66.4   Max: 76.1
Current: 61.7

-66.4
76.1
» JAZZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

JAZZ Guru Trades in Q1 2013

Paul Tudor Jones 5,500 sh (New)
Steven Cohen 395,645 sh (+79.97%)
RS Investment Management 666,190 sh (+16.46%)
John Paulson 1,000,000 sh (unchged)
Pioneer Investments 1,048,381 sh (-8.37%)
Jim Simons 8,900 sh (-98.6%)
» More
Q2 2013

JAZZ Guru Trades in Q2 2013

Chuck Royce 184,000 sh (New)
NWQ Managers 198,679 sh (New)
Jim Simons 146,800 sh (+1549.44%)
Paul Tudor Jones 8,200 sh (+49.09%)
Steven Cohen Sold Out
RS Investment Management 665,603 sh (-0.09%)
John Paulson 963,000 sh (-3.7%)
Pioneer Investments 421,059 sh (-59.84%)
» More
Q3 2013

JAZZ Guru Trades in Q3 2013

Steven Cohen 2,680 sh (New)
RS Investment Management 730,583 sh (+9.76%)
John Paulson 963,000 sh (unchged)
Jim Simons Sold Out
NWQ Managers 193,233 sh (-2.74%)
Chuck Royce 150,300 sh (-18.32%)
Pioneer Investments 328,378 sh (-22.01%)
Paul Tudor Jones 5,500 sh (-32.93%)
» More
Q4 2013

JAZZ Guru Trades in Q4 2013

Steven Cohen 9,178 sh (+242.46%)
John Paulson Sold Out
Chuck Royce 140,600 sh (-6.45%)
Pioneer Investments 241,827 sh (-26.36%)
NWQ Managers 137,154 sh (-29.02%)
RS Investment Management 403,383 sh (-44.79%)
Paul Tudor Jones 2,937 sh (-46.6%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2013-12-31 Sold Out 0.57%$82.62 - $126.79 $ 136.1632%0
John Paulson 2012-09-30 New Buy0.47%$44.4 - $58.5 $ 136.16182%1000000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Jazz Pharmaceuticals PLC

Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI
According to GuruFocus Insider Data, the largest insider sells over the past week were: Jazz Pharmaceuticals PLC, Home Depot Inc., Express Scripts and Service Corporation International Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.60
JAZZ's P/E(ttm) is ranked higher than
55% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. JAZZ: 38.60 )
JAZZ' s 10-Year P/E(ttm) Range
Min: 10.72   Max: 51.7
Current: 38.6

10.72
51.7
P/B 6.08
JAZZ's P/B is ranked higher than
52% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. JAZZ: 6.08 )
JAZZ' s 10-Year P/B Range
Min: 2.46   Max: 32.21
Current: 6.08

2.46
32.21
P/S 9.62
JAZZ's P/S is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. JAZZ: 9.62 )
JAZZ' s 10-Year P/S Range
Min: 0.22   Max: 12.01
Current: 9.62

0.22
12.01
PFCF 30.88
JAZZ's PFCF is ranked higher than
63% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. JAZZ: 30.88 )
JAZZ' s 10-Year PFCF Range
Min: 11.82   Max: 38.56
Current: 30.88

11.82
38.56
EV-to-EBIT 22.98
JAZZ's EV-to-EBIT is ranked higher than
51% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. JAZZ: 22.98 )
JAZZ' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 30.6
Current: 22.98

9.4
30.6
PEG 0.57
JAZZ's PEG is ranked higher than
88% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. JAZZ: 0.57 )
JAZZ' s 10-Year PEG Range
Min: 0   Max: 4.8
Current: 0.57

0
4.8
Shiller P/E 215.64
JAZZ's Shiller P/E is ranked lower than
68% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. JAZZ: 215.64 )
JAZZ' s 10-Year Shiller P/E Range
Min: 181.79   Max: 11692
Current: 215.64

181.79
11692

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 243.14
JAZZ's Price/Tangible Book is ranked lower than
92% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. JAZZ: 243.14 )
JAZZ' s 10-Year Price/Tangible Book Range
Min: 11.71   Max: 226
Current: 243.14

11.71
226
Price/DCF (Projected) 3.61
JAZZ's Price/DCF (Projected) is ranked higher than
50% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. JAZZ: 3.61 )
JAZZ' s 10-Year Price/DCF (Projected) Range
Min: 2.51   Max: 3.36
Current: 3.61

2.51
3.36
Price/Median PS Value 2.56
JAZZ's Price/Median PS Value is ranked lower than
67% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. JAZZ: 2.56 )
JAZZ' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 2.38
Current: 2.56

0.2
2.38
Price/Graham Number 19.76
JAZZ's Price/Graham Number is ranked lower than
85% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. JAZZ: 19.76 )
JAZZ' s 10-Year Price/Graham Number Range
Min: 2.62   Max: 18.37
Current: 19.76

2.62
18.37
Earnings Yield (Greenblatt) 4.40
JAZZ's Earnings Yield (Greenblatt) is ranked higher than
60% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. JAZZ: 4.40 )
JAZZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.3   Max: 10.7
Current: 4.4

3.3
10.7
Forward Rate of Return (Yacktman) -0.37
JAZZ's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. JAZZ: -0.37 )
JAZZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -44.4   Max: -0.4
Current: -0.37

-44.4
-0.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:J7Z.Germany
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. It applies novel formulations and drug delivery technologies to known drug compounds, and to compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by, among other things, improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. The company's marketed products and late-stage product candidate are: Xyrem (sodium oxybate) oral solution, Xyrem is approved by the U.S. Food and Drug Administration for the treatment of both excessive daytime sleepiness and cataplexy in patients with narcolepsy. Narcolepsy is a chronic neurologic disorder caused by the brain's inability to regulate sleep-wake cycles; Luvox CR (fluvoxamine maleate) Extended-Release Capsules, Once-Daily Luvox CR was approved by the FDA for the treatment of both obsessive compulsive disorder and social anxiety disorder; JZP-6 (sodium oxybate), developed for the treatment of fibromyalgia.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide